SCHEMBL2929916

SCHEMBL2929916

C=Cn1cc(Cl)c(=O)[nH]c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 2/20 0.38
GRIA2 P42262 2/20 0.38
GRIA4 P48058 2/20 0.38
GRIK5 Q16478 1/20 0.38
PYGM P11217 1/20 0.34
DAO P14920 5/20 0.32
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
GRIN2D O15399 1/20 0.31
GRIN3B O60391 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
CYP1A2 P05177 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
TSHR P16473 1/20 0.31
THPO P40225 1/20 0.31
GRIA3 P42263 1/20 0.31
BLM P54132 1/20 0.31
PMP22 Q01453 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL933036 0.76 TK1 (0.43) GRIA1GRIA2GRIA4GRIK5PYGM
SCHEMBL9332865 0.73 TK1 (0.40) DAOMEN1ALDH1A1CYP1A2KMT2A
SCHEMBL4379053 0.68 DAO (0.43) GRIA1GRIA2GRIA4GRIK5PYGM
SCHEMBL9192075 0.68 TDP1 (0.57) GRIA1GRIA2GRIA4GRIK5PYGM
SCHEMBL12702585 0.65 GRIA1 (0.39) GRIA1GRIA2GRIA4GRIK5PYGM
SCHEMBL11254252 0.64 GRIA1 (0.53) GRIA1GRIA2GRIA4GRIK5MEN1
SCHEMBL7204552 0.63 CRBN (0.48) ALDH1A1LMNA
SCHEMBL9891079 0.62 GRIA1 (0.47) GRIA1GRIA2GRIA4GRIK5
SCHEMBL19711624 0.62 GRIA1 (0.54) GRIA1GRIA2GRIA4GRIK5PYGM
SCHEMBL30423828 0.60 GRIA1 (0.60) GRIA1GRIA2GRIA4GRIK5DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118931997-A Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis 上海飞腾医药科技有限公司 2024-11-12 CN claimed
CN-118931997-A Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis 上海飞腾医药科技有限公司 2024-11-12 CN disclosed
EP-1925675-B1 Process for production of nucleoside compound MITSUI CHEMICALS INC (JP) 2010-02-03 EP disclosed
EP-1338654-B1 PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND MITSUI CHEMICALS INC (JP) 2008-10-15 EP disclosed
EP-1178051-B1 PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE MITSUI CHEMICALS INC (JP) 2008-05-28 EP disclosed
EP-1925675-A1 Process for production of nucleoside compound Mitsui Chemicals, Inc. (JP) 2008-05-28 EP disclosed
US-20060094869-A1 Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside MITSUI CHEMICALS, INC. (JP) 2006-05-04 US disclosed
US-7038039-B2 Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside MITSUI CHEMICALS, INC. (JP) 2006-05-02 US disclosed
EP-1179598-B1 PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND MITSUI CHEMICALS INC (JP) 2005-08-10 EP disclosed
US-20040219646-A1 Process for producing nucleoside compound MITSUI CHEMICALS, INC. (JP) 2004-11-04 US disclosed
EP-1179598-A1 PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND Mitsui Chemicals, Inc. (JP) 2002-02-13 EP disclosed
EP-1178051-A2 PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE Mitsui Chemicals, Inc. (JP) 2002-02-06 EP disclosed
EP-1177201-A1 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES YAMASA CORPORATION (JP) 2002-02-06 EP disclosed
EP-1177202-A1 4'-C-ETHYNYL PURINE NUCLEOSIDES YAMASA CORPORATION (JP) 2002-02-06 EP disclosed
US-6333315-B1 FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) YAMASA CORPORATION (JP) 2001-12-25 US disclosed
US-6291670-B1 VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) YAMASA CORPORATION (JP) 2001-09-18 US disclosed
WO-2000069876-A1 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES YAMASA CORPORATION (JP) 2000-11-23 WO disclosed
WO-2000069877-A1 4'-C-ETHYNYL PURINE NUCLEOSIDES YAMASA CORPORATION (JP) 2000-11-23 WO disclosed
US-5811408-A ANTITUMOR AND ANTICARCINOGENIC AGENT; INTRODUCING SULFONYL GROUP ON HYDROXY GROUP OF TETRAHYDROFURAN RING, HYDROLYSIS, BLOCKING, OXIDATION, WITTING REACTION, DEPROTECTION AND PHOSPHORYLATION YAMASA CORPORATION (JP) 1998-09-22 US disclosed
EP-0770621-A1 2'-DEOXY-2'-(SUBSTITUTED OR UNSUBSTITUTED METHYLIDENE)-4'-THIONUCLEOSIDE YAMASA CORPORATION (JP) 1997-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094869-A1 Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside PNP, MTAP, GALE GRIA1 2465/4885GRIA2 3185/4885GRIA4 2729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.